Cell and Gene Therapy's Trillion-Dollar Reckoning Is Here
Lakshmi, Editorial Team, Pharma Focus Europe
Cell and gene therapies are transforming medicine, but commercial sustainability remains their greatest challenge. Despite scientific breakthroughs and a rapidly expanding pipeline, many developers face slow adoption, reimbursement hurdles, and unsustainable business models. This article explores why market access, pricing, payer alignment, and scalable financing—not clinical innovation alone—will determine which companies succeed as the industry enters its next phase of growth.
Introduction:
Cell and gene therapies can cure diseases once thought untreatable. Yet a string of commercial collapses now suggests that curing the patient and sustaining the business are two very different challenges — and the industry is confronting the gap at last.
For most of the past decade, cell and gene therapy sold a story that was almost too good to argue with. One infusion. A lifetime of disease undone. A child with sickle cell disease who might never see the inside of an emergency room again. The science delivered on much of that promise. The business proved a harder problem — and the industry is now living through a reckoning it spent years postponing.
From a distance, the numbers still look intoxicating. Analysts value the global market at roughly $25 billion in 2025, climbing towards $115 billion by 2035 at a compound annual growth rate above 16 per cent. More than 2,000 therapies sit in the pipeline, and dozens have already been approved. But a growing market and a functioning one are not the same thing, and the gap between them is where companies are quietly going broke.
The uncomfortable truth the sector is finally stating aloud is simple: a cure that cannot be sold is not a cure. It is a science project with a balance sheet attached.
The Pioneer That Couldn’t Fly
No single story captures the reckoning better than that of one of the field's original pioneers — a company admired for three decades as one of the most respected names in gene therapy. It reached the market with three therapies approved by the US Food and Drug Administration (FDA), each targeting a severe genetic disease: one for beta-thalassemia, one for sickle cell disease, and one for a rare and devastating brain disorder. On paper, it was a portfolio most biotech firms would envy.
In practice, it became a slow-motion collapse. The therapies worked; the market did not cooperate. Uptake crawled. By late 2024, the company had recorded only 57 patient starts across all three products. It shed a quarter of its workforce, carried out a reverse stock split to avoid being delisted, and burned through cash it no longer had. Its accumulated deficit had passed $4 billion.
The ending would have been unthinkable at the company's peak. In early 2025, a firm once counted among the buzziest names in biotech sold itself to two private equity houses for around $30 million. Shareholders received $3 a share, for a stock that had traded far higher for years. The company that helped invent the very idea of a one-time genetic cure was, in effect, sold for scrap and renamed.
The postscript is quietly telling. By late 2025, under new ownership, fewer than 40 patients had received its sickle cell therapy and around 80 its thalassemia product — this for a sickle cell treatment whose eligible US population runs to roughly 20,000 people. The science reached almost no one. That is the reckoning in miniature: not a failure of the medicine, but of everything wrapped around it.
Why a Cure Is Hard to Sell
The instinct is to blame the price tags, and the price tags are genuinely staggering. Approved therapies range from roughly $370,000 to well over $4 million per patient. Some carry list prices close to $2.8 million. When one developer priced its therapy at $1.8 million in Europe, payers balked so sharply that the company withdrew it from the continent within two years of approval.
Price alone, though, does not explain the trouble. The deeper problem is a collision of incentives that healthcare systems were never built to handle.
The mismatch runs as follows. A gene therapy delivers its value over decades — a lifetime free of transfusions, hospital stays and crises. An insurer's relationship with any given member, however, often lasts only a few years before that person changes jobs, changes plans, or moves onto a government scheme. The payer therefore writes a multimillion-dollar cheque today for a benefit that will mostly accrue to a rival insurer later. In cold actuarial terms, it pays full price to subsidise a competitor's future savings.
Providers face their own squeeze. The treatment journey for these therapies can take nine months and involve multiple stem-cell collections, specialised manufacturing and a long operational tail — all before a single dollar of revenue is recognised, because firms typically record revenue only on delivery rather than when a patient begins the process.
Trust is thin. Around 60 per cent of payers doubt the long-term value models used to justify one-time gene therapies. Only about one insurer in five has adopted outcomes-based payment arrangements — the very contracts designed to make these therapies affordable. Almost everyone agrees that reimbursement machinery built for chronic drugs, taken daily for years, does not fit a product given once. Far fewer agree on what should replace it.
When Free Is the Last Resort
The clearest measure of how strained the economics have become is this: at least one developer has offered its gene therapy at no cost — giving the product away — because the reimbursement pathway was so tangled that free proved easier than fighting for coverage.
The detail deserves a pause. In few other corners of the pharmaceutical industry does a company hand over a breakthrough for nothing because the payment system is too broken to accept the bill.
It is not generosity but a symptom. When the machinery of pricing and access seizes up, "free" becomes a commercial strategy — a way to reach patients and build a real-world evidence base while the reimbursement fight plays out in the background. It is also a warning light for every executive watching: securing approval is now the easy part.
The market has already taught the harsher lesson. In 2024, a newly approved gene therapy was pulled from sale only months after launch — not because it stopped working, but because it lacked a sound commercial strategy and any payer appetite to sustain it. Approval was once the finish line. It is now barely the starting gun.
The Scale Paradox
A paradox sits beneath all of this, and it is the one keeping strategists awake.
Cell and gene therapies are, for now, boutique products — a handful of patients per centre, sometimes one every few months. The current distribution and payment models, clumsy as they are, largely hold together precisely because the volumes are tiny. As one industry leader put it at a 2026 specialty-pharmacy summit, the models may not be broken today, but the real question is whether they break the moment the field scales — the moment it is no longer one patient every six months.
That is the trap. Everyone wants the field to grow; growth is the entire investment case. Yet the very success the sector chases — dozens of approved therapies, thousands of eligible patients, mainstream adoption — is exactly what could shatter a payment system that only functions at boutique volume. The industry is racing towards a finish line that may collapse the track beneath it.
Cracks of Light
None of this means the field is doomed. The reckoning is a maturation, not an obituary, and the smarter players are treating it as such.
The diversity of the pipeline is itself part of the answer. Not every advanced therapy is a $4 million one-shot. Some CAR-T therapies — treatments that re-engineer a patient's own immune cells to attack disease — cost $400,000 to $500,000. Still steep, but far easier for a payer to absorb than a single $4 million charge. Some newer therapies are given in sequence rather than all at once, spreading the cost into instalments that health systems can manage. As one access strategist observed, a field in which every programme cost $3 million per patient in perpetuity would simply collapse; the growing variety is what keeps it upright.
Policy is inching forward too. Medicare payments for CAR-T therapy are set to rise in the 2026 fiscal year, improving hospital economics. A US innovation body has struck an access model with manufacturers for sickle cell gene therapies. Academic groups are proposing stepwise financing frameworks that begin with private-market fixes and escalate to public-private hybrids only where needed. None is a silver bullet. All are incremental. And incremental, in a field this young, is how durable markets are actually built
| Pressure point | The problem | Why it matters commercially |
| The price | Approved therapies cost roughly $370,000 to over $4 million per patient | Health systems built for chronic, recurring drugs struggle to absorb a single large upfront charge |
| The timing mismatch | Benefits accrue over decades; insurers keep members only a few years | Payers fund a cure whose savings largely reach a rival insurer later |
| The trust gap | About 60% of payers doubt long-term value models; only ~20% use outcomes-based deals | Reimbursement negotiations stall, delaying or blocking patient access |
| The scale question | Current models work only at boutique volume | Wider adoption — the industry's goal — could break the very system meant to pay for it |
The Cure Was Never the Hard Part
The lesson of the past two years is now burned into the industry: the science is no longer the differentiator. Access is.
The firms that survive this reckoning will not necessarily be those with the most elegant vector or the highest efficacy readout. They will be the ones that arrive with a reimbursement strategy already built, a value story payers believe, and a commercial model designed for the messy realities of who pays, when and for how long. The pioneers of the field had the science. What they lacked was everything else — and everything else is what decides who survives.
The trillion-dollar promise of cell and gene therapy was always real. What the industry underestimated is that curing a disease is only half an achievement. The other half — the unglamorous, spreadsheet-bound work of making that cure something a health system can actually buy — separates the pioneers who make history from those who become cautionary tales.
The reckoning has arrived. The therapies can already change lives. The only question left is whether the organisations that make them can build businesses strong enough to keep the promise — or whether the greatest cures of a generation will end up as breakthroughs the world could not afford to use.
Lakshmi is a science writer with a foundation in the laboratory. She earned her master's in biotechnology and trained through research internships at ICGEB (JNU) and DIPAS, DRDO, with her work appearing in the Egyptian Journal of Veterinary Sciences. Now APCRM-certified and part of the editorial team at Pharma Focus America and Pharma Focus Europe, she reports on pharmaceutical technology, research, and innovation — giving complex science a clear and confident voice for industry leaders.
